S. Lehrman

发表

Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity.

L. Corey, D. Barry, J. Douglas, 1986, Annals of internal medicine.

ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

E. Gelmann, H. Mitsuya, S. Broder, 1986, The Lancet.

Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis

H. Einsele, F. Baldanti, G. Fahle, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir.

D. Alling, S. Straus, J. DiGiovanna, 1984 .

Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity

S. Straus, J. Rooney, D. Barry, 1987, Antimicrobial Agents and Chemotherapy.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS.

S. Lehrman, F. Noronha, C. Roneker, 1987, Cancer research.

Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates

D. Barry, S. Lehrman, P. Keller, 1985, Antimicrobial Agents and Chemotherapy.

Herpes simplex encephalitis in a patient with lymphoma. Relapse following acyclovir therapy.

A. Rothman, A. Cederbaum, S. Lehrman, 1988, JAMA.

Double-blind comparison of weekend and daily regimens of oral acyclovir for suppression of recurrent genital herpes.

H. Krakauer, J. Rooney, S. Straus, 1986, Antiviral research.

Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group.

W. Parks, R. McKinney, S. Lehrman, 1990, The Journal of pediatrics.

General Considerations of Viral Respiratory Diseases

S. Lehrman, 1985 .

Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment.

C. Hallahan, M. Sawyer, S. Straus, 1988, JAMA.

Asking the right questions: developing evidence-based strategies for treating HIV in women and children

J. Montaner, P. Cahn, R. Wood, 2011, BMC public health.

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Broder, H. Mitsuya, S. Broder, 1986, Proceedings of the National Academy of Sciences of the United States of America.

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

D W Barry, H. Mitsuya, S. Broder, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Zidovudine improves psoriasis in human immunodeficiency virus-positive males.

J. Reveille, M. Duvic, S. Lehrman, 1994, Archives of dermatology.

Extended acyclovir therapy for herpes genitalis: changes in virus sensitivity and strain variation.

S. Straus, J. Rooney, D. Barry, 1986, The Journal of antimicrobial chemotherapy.

Treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex with a regimen of 3'-azido-2',3'-dideoxythymidine (azidothymidine or zidovudine) and acyclovir. A pilot study.

H. Mitsuya, M. Leuther, R. Yarchoan, 1988, Annals of internal medicine.

Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy.

B. Bean, J. Englund, C. Fletcher, 1987, Diagnostic microbiology and infectious disease.

Clinical and laboratory experience with acyclovir-resistant herpes viruses.

D. Barry, S. Lehrman, M. Ellis, 1986, The Journal of antimicrobial chemotherapy.

C4B Deficiency: A Risk Factor for Bacteremia with Encapsulated Organisms

J. L. Martin, J. Mills, P. Collins, 1990 .

Prophylactically administered Retrovir in health care workers potentially exposed to the human immunodeficiency virus.

D. Barry, S. Lehrman, S. Lafon, 1988, The Journal of infectious diseases.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Common Viral Respiratory Illnesses

S. Lehrman, 1985 .

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.

M. Wulfsohn, R. Gelber, W. Borkowsky, 1991, The New England journal of medicine.

Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 3'-azido-3'-deoxythymidine in vitro

T. Matsui, A. Matsuda, R. Gallo, 1986, Antimicrobial Agents and Chemotherapy.